What Are the Qualifications for Wegovy in the UK?

Does your BMI alone qualify you for Wegovy?

BMI is the first filter, but it has never been the whole answer. The licensed threshold is a BMI of 30 or above, or 27 to 29.9 if you have at least one weight-related condition alongside it. Qualifying conditions in that second group include type 2 diabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea and cardiovascular disease, among others.

For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance recognises that health risks associated with excess weight emerge at lower BMI values. The thresholds are generally set 2.5 kg/m² below the standard figures, so 27.5 rather than 30 for the lower band, for example. If you are unsure which applies to you, the detailed eligibility breakdown walks through the categories clearly.

It is also worth knowing that BMI is a population-level tool rather than a precise individual measure. A prescriber may consider waist circumference, metabolic markers and overall health context alongside it. Someone with a BMI just below a threshold but significant metabolic risk may still be considered; someone who technically clears the number but has a contraindication will not be approved. Once you have been approved and are ready to begin, reading through how to use Wegovy correctly will help you get the most from your treatment from the very first dose. The NHS BMI calculator at nhs.uk gives you a quick starting reference if you want to check your own figure before consulting.

What health conditions can support eligibility at a lower BMI?

If your BMI sits between 27 and 29.9, the presence of a qualifying comorbidity is what opens the door. Type 2 diabetes is one of the most common reasons people are considered at this range, and it is worth noting that semaglutide has a separate diabetes licence (as Ozempic), but Wegovy's weight-management licence is a distinct authorisation with its own clinical criteria. The two are not interchangeable, and the difference between Wegovy and Ozempic matters practically as well as legally.

High blood pressure and high cholesterol are frequently present in people who would benefit from weight management treatment, and both count toward eligibility. Obstructive sleep apnoea is increasingly recognised as a weight-related condition that responds well to meaningful weight loss, so it appears in the qualifying list. Cardiovascular disease (broadly defined) is also included. The point is not to match yourself to a list and self-certify; a prescriber will verify these conditions as part of the consultation, which is why providing accurate medical history matters.

For a fuller picture of contraindications that could prevent approval regardless of BMI, the Wegovy contraindications page covers the conditions and medicines that require careful prescriber assessment. Honesty at the consultation stage is the safest approach for everyone.

How do NHS and private qualifications for Wegovy differ?

The licensed eligibility criteria described above apply to any legitimate UK prescriber, NHS or private. What differs is the layer of additional requirements the NHS places on top. NICE's appraisal of semaglutide (TA875) recommends Wegovy on the NHS only for adults using a specialist weight management service, with multidisciplinary support, and for a maximum of two years. BMI thresholds on the NHS are typically 35 or above (with a weight-related comorbidity), or 30 to 34.9 where specialist-referral criteria are met. Waiting lists for those services are long in most parts of England.

Private prescribing follows the licensed criteria directly: BMI 30 or above, or 27 or above with a qualifying condition, assessed by a registered prescriber. There is no two-year NHS cap and no referral requirement. For people who meet the licensed threshold but not the stricter NHS criteria, or who cannot wait, a regulated private route is the practical alternative. If you are weighing up how Wegovy compares to other licensed options, that context may be relevant to your decision.

One practical note: orders placed by midday on a working day are reviewed the same day, so if you are considering starting before a busy period (the end of the month, a holiday, a long weekend) timing your consultation gives you the best chance of a smooth start. A real clinician reads your answers; it is not automated.

What happens if you do not meet the qualifications?

Not qualifying for Wegovy at this point is not a closed door. BMI changes, comorbidities are sometimes identified through GP review, and the range of licensed medicines available in the UK has widened recently. Tirzepatide (Mounjaro) carries the same core BMI thresholds and is the only dual GIP and GLP-1 receptor agonist licensed here, with trial evidence showing greater average weight reduction than semaglutide at comparable doses in the SURMOUNT-5 study published in the New England Journal of Medicine (2025). Understanding which option fits your situation is a clinical conversation, not a product choice.

Oral semaglutide (Wegovy tablets), approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management, follows the same BMI thresholds as the injection. If the injection format is a barrier, that may be worth raising at consultation. The weight-loss treatment overview covers the currently licensed options in plain terms, and our clinical team is there to help you find what fits your medical history, not to push a particular product.

The cost of treatment is a fair question too. A contextual sense of what private Wegovy prescriptions typically involve is covered on the Wegovy access page, and NICE's published recommendation (TA875) sets out the full evidence base the appraisal committee considered if you want the clinical detail. The right starting point is a free consultation where a prescriber reviews your situation properly.